Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felmetatug Vedotin in Advanced Solid Tumors
NCT05194072Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Jan 2022
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of sgn-b7h4v in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC) and 8 more (2 arms), sponsored by Pfizer. Primary endpoints: Adverse Events, Laboratory Abnormalities and 2 more. Started Jan 2022; status: terminated.
02
Drugs
sgn-b7h4v
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on NCT05194072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05194072.